Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue.
about
α1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?Caveolae contribute to the apoptosis resistance induced by the alpha(1A)-adrenoceptor in androgen-independent prostate cancer cellsThe role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms.Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia.Silodosin in the treatment of benign prostatic hyperplasiaUse of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil.Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions.Quantification and distribution of alpha1-adrenoceptor subtype mRNAs in human proximal urethraEffects of castration on contraction and alpha(1)-adrenoceptor expression in rat prostate.Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia.Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.Mechanistic insights into the role of alpha1adrenergic receptors in lower urinary tract symptoms.Phenotype pharmacology of lower urinary tract α(1)-adrenoceptors.Current models of human prostate contractility.Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate.Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.The alpha1A-adrenoceptor gene is required for the alpha1L-adrenoceptor-mediated response in isolated preparations of the mouse prostatePharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system.Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction : implications for sexual dysfunction.Genetic polymorphism and pathogenesis of benign prostatic hyperplasia.Subtypes of alpha1-adrenoceptors in BPH: future prospects for personalized medicine.Expression and function of G-protein-coupled receptors in the male reproductive tract.Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates.Prostatic α1-adrenoceptors: new concepts of function, regulation, and intracellular signaling.Management of benign prostatic hyperplasia with silodosinNon-Hormonal treatment of BPH/BOOLatest pharmacotherapy options for benign prostatic hyperplasia.Prostatic Artery Embolization (PAE) for Symptomatic Benign Prostatic Hyperplasia (BPH): Part 2, Insights into the Technical Rationale.Current and emerging therapies in premature ejaculation: Where we are coming from, where we are going.Alpha 1-adrenoceptor blocker may improve not only voiding but also storage lower urinary tract symptoms caused by (125) I brachytherapy for prostate cancer.Pharmacological characterization of N1-(2-methoxyphenyl)-N4-hexylpiperazine as a multi-target antagonist of α1A/α1D-adrenoceptors and 5-HT1A receptors that blocks prostate contraction and cell growth.Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia.Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: sildenafil and papaverin generate inhibition.Age Related Differences in Responsiveness to Sildenafil and Tamsulosin are due to Myogenic Smooth Muscle Tone in the Human Prostate.Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia.Effect of KMD-3213, an alpha1A-adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs.The role of alpha1D-adrenoceptors in prostatic contraction examined using protection studies.Alpha-blocker test: alternative to pressure-flow study of bladder outlet obstruction and detrusor contractility in patients without an enlarged prostate.1,3-Dioxolane-based ligands as rigid analogues of naftopidil: structure-affinity/activity relationships at alpha1 and 5-HT1A receptors.
P2860
Q28070342-50C013AA-79D7-4E9E-8F8D-DB62738F2B63Q28476183-A8F8E4EE-F128-4D85-A163-6EB2686B239DQ34394068-49B105F8-D7E9-4DA7-BC6D-A5FD429895EBQ34585420-1166D51C-C5DC-4404-A69A-45DB7A54E405Q34625490-0995B59D-4000-4C92-A3DB-CA343BABDDDAQ34988813-3C23993B-9804-43DC-9BC6-A640E5208676Q35026860-3C9AD9E9-4291-427B-844F-2599EB9911F4Q35027384-0958D47D-B45F-47EF-872A-F17F421FF256Q35042953-C4867D82-BD39-4E74-AF52-393A8E20298AQ35093140-4403B397-50DD-4A8C-BEDB-E47D07775A49Q35545711-7F600057-0452-4FBE-9E8B-F11736219ED3Q35839585-CB231D97-AB7D-4E28-9847-1E21E7CEDF52Q36024814-10542837-3F4E-46B2-A89E-747D3584DB32Q36262202-896DB7D8-979C-4EDB-A44B-DA4789BA9C44Q36360868-C3E41FD2-EA8E-42F8-9E81-6CCFF5491101Q36428505-6AF1B275-FF64-49E0-8759-D7E7EE09EF68Q36858288-B6BF7801-C646-4082-A145-6A2000D4F472Q36872293-20B1FAB3-6BCF-4BCE-BECA-3F5C2C9915D7Q37058005-E2B236EC-D73E-499F-9AE2-3F4CAA11B16CQ37137949-498E2147-8F85-4DD8-B8B8-07BD9C5D9D99Q37365172-4F18379F-0E82-4739-BD4A-96AF4FE21ED7Q37590172-5272764E-3A29-4DEC-BCB0-40E2372D8F39Q38081486-C010E7BD-1B81-4A39-A1BA-B66A828BE311Q38137877-505D1E87-B90F-4418-B9FE-AA930513E867Q38160469-476B2C01-A84F-4ACF-9316-5FD77FCB2677Q38205423-8F56D2B6-AA9A-436F-B8D1-962603D237F7Q38244053-0121D1C7-CB7F-4566-8386-AEFD976522E5Q38631990-4F79DED8-F77C-4CC8-A9BB-6C5F9CE098E8Q38972605-77E62AC7-45D5-44C3-83E6-B721E04F73C5Q39041552-E16796E9-8AFF-4C76-B0C6-4FF60B104703Q39064824-92D5ECEE-51F2-4336-BB14-09171E8A9BF0Q39353700-926D8C83-0279-452D-9AD5-D82698FA0550Q39375083-FE269078-21E8-4C8D-8677-7AEDE2EE042EQ40650047-D224A899-5F63-4221-AF4F-35F6A5FF1CD4Q41579675-CDA458C8-2CB9-4853-BC0B-3FC7DC469FE4Q42780748-E4ADA1BF-7A2F-4E0A-8196-AFE457C9B21EQ43548872-5BD62E9F-7C33-484D-B11A-3906D4613B76Q44515716-6E270638-3C5A-4A2F-88D8-1DDA49722A0FQ44695184-72C2E6F0-1B96-41AA-B65D-96AFDEAD0352Q46157845-6E46E486-299B-440C-A856-B4B8375E8484
P2860
Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Quantification and distributio ...... and non-hypertrophied tissue.
@ast
Quantification and distributio ...... and non-hypertrophied tissue.
@en
type
label
Quantification and distributio ...... and non-hypertrophied tissue.
@ast
Quantification and distributio ...... and non-hypertrophied tissue.
@en
prefLabel
Quantification and distributio ...... and non-hypertrophied tissue.
@ast
Quantification and distributio ...... and non-hypertrophied tissue.
@en
P2093
P2860
P1476
Quantification and distributio ...... and non-hypertrophied tissue.
@en
P2093
Moriyama N
Tsujimoto G
P2860
P304
P356
10.1111/J.1476-5381.1996.TB15742.X
P407
P577
1996-11-01T00:00:00Z